The new medicine approved for weight loss is Zepbound, manufactured by Lilly.
Zepbound: A Dual-Agonist Approach
Zepbound (tirzepatide) is a dual-agonist drug that targets two key hormones involved in appetite regulation:
- GLP-1 (Glucagon-like Peptide-1): This hormone is already targeted by other weight loss medications.
- Additional Hormone: Zepbound uniquely targets a second hormone to further regulate appetite and promote feelings of fullness.
Key Facts About Zepbound
| Feature | Description |
|---|---|
| Manufacturer | Lilly |
| Active Ingredient | Tirzepatide |
| Mechanism | Dual-agonist targeting GLP-1 and another appetite-regulating hormone. |
| Initial Approval | Approved in 2022 as Mounjaro for diabetes. |
| Weight Loss Approval | Approved in 2023 as Zepbound for weight loss. |
How it Works
Zepbound's dual-action mechanism provides a more comprehensive approach to weight management by:
- Reducing Appetite: By stimulating GLP-1 receptors and an additional hormone, Zepbound helps decrease hunger.
- Promoting Fullness: Users tend to feel fuller for longer, leading to reduced calorie intake.
